PuSH - Publikationsserver des Helmholtz Zentrums München: Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis "

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Justet, A* ; Wagner, D.E.* ; Königshoff, M.* ; Alsafadi, H.N.* ; Mitash, N.* ; Justet, A.* ; Hu, Q.* ; Pineda, R.* ; Staab-Weijnitz, C.A.* ; Korfei, M.* ; Mutze, K.* ; Costa, R.* ; Bolukbas, D.* ; Stegmayr, J.* ; Skronska-Wasek, W.* ; Ota, C.* ; Baarsma, H.A.* ; Sembrat, J.* ; Hilgendorff, A.* ; Günther, A.* ; Chambers, R.C.* ; de Langhe, S.* ; Kaminski, N.* ; Lehmann, M.* ; Eickelberg, O.*

Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis "

(2024)

Abstract
Metriken
Zusatzinfos

Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal disease characterized by excessive extracellular matrix (ECM) deposition. Current IPF therapies slow disease progression but do not stop or reverse it. The (myo)fibroblasts are thought to be the main cellular contributors to excessive ECM production in IPF. Here we report that fibrotic AT2 cells regulate production and crosslinking of ECM via the co-transcriptional activator YAP. YAP leads to increase expression of Lysyloxidase (LOX) and subsequent LOX mediated crosslinking by fibrotic AT2 cells. Pharmacological YAP inhibition reverses fibrotic AT2 cell reprogramming and LOX expression in experimental lung fibrosis in vivo and in human fibrotic tissue ex vivo. We thus identify YAP-TEAD/LOX inhibition in AT2 cells as a promising potential new therapy for IPF patients.